RU2727451C2 - Т-клетки, модифицированные химерным рецептором антигена, нацеленным на cs1 - Google Patents

Т-клетки, модифицированные химерным рецептором антигена, нацеленным на cs1 Download PDF

Info

Publication number
RU2727451C2
RU2727451C2 RU2017121826A RU2017121826A RU2727451C2 RU 2727451 C2 RU2727451 C2 RU 2727451C2 RU 2017121826 A RU2017121826 A RU 2017121826A RU 2017121826 A RU2017121826 A RU 2017121826A RU 2727451 C2 RU2727451 C2 RU 2727451C2
Authority
RU
Russia
Prior art keywords
gly
ser
leu
pro
val
Prior art date
Application number
RU2017121826A
Other languages
English (en)
Russian (ru)
Other versions
RU2017121826A3 (cg-RX-API-DMAC7.html
RU2017121826A (ru
Inventor
Стивен Дж. ФОРМЭН
Сюли ВАН
Original Assignee
Сити Оф Хоуп
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Сити Оф Хоуп filed Critical Сити Оф Хоуп
Publication of RU2017121826A publication Critical patent/RU2017121826A/ru
Publication of RU2017121826A3 publication Critical patent/RU2017121826A3/ru
Application granted granted Critical
Publication of RU2727451C2 publication Critical patent/RU2727451C2/ru

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70521—CD28, CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/31—Chimeric antigen receptors [CAR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/35—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Mycobacteriaceae (F)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • C12N5/0637—Immunosuppressive T lymphocytes, e.g. regulatory T cells or Treg
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • C12N5/0638—Cytotoxic T lymphocytes [CTL] or lymphokine activated killer cells [LAK]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5156—Animal cells expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5158—Antigen-pulsed cells, e.g. T-cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/526—CH3 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/53—Hinge
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/033—Fusion polypeptide containing a localisation/targetting motif containing a motif for targeting to the internal surface of the plasma membrane, e.g. containing a myristoylation motif
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Hematology (AREA)
  • General Engineering & Computer Science (AREA)
  • Toxicology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Mycology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Virology (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
RU2017121826A 2014-12-05 2015-12-07 Т-клетки, модифицированные химерным рецептором антигена, нацеленным на cs1 RU2727451C2 (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462088423P 2014-12-05 2014-12-05
US62/088,423 2014-12-05
PCT/US2015/064303 WO2016090369A1 (en) 2014-12-05 2015-12-07 Cs1 targeted chimeric antigen receptor-modified t cells

Publications (3)

Publication Number Publication Date
RU2017121826A RU2017121826A (ru) 2019-01-10
RU2017121826A3 RU2017121826A3 (cg-RX-API-DMAC7.html) 2019-07-17
RU2727451C2 true RU2727451C2 (ru) 2020-07-21

Family

ID=55069093

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2017121826A RU2727451C2 (ru) 2014-12-05 2015-12-07 Т-клетки, модифицированные химерным рецептором антигена, нацеленным на cs1

Country Status (12)

Country Link
US (3) US10821161B2 (cg-RX-API-DMAC7.html)
EP (2) EP3227315B1 (cg-RX-API-DMAC7.html)
JP (2) JP7098325B2 (cg-RX-API-DMAC7.html)
KR (1) KR102558502B1 (cg-RX-API-DMAC7.html)
CN (2) CN107429253B (cg-RX-API-DMAC7.html)
AU (2) AU2015357485B2 (cg-RX-API-DMAC7.html)
BR (1) BR112017011893A2 (cg-RX-API-DMAC7.html)
CA (1) CA2969704C (cg-RX-API-DMAC7.html)
IL (3) IL290459B2 (cg-RX-API-DMAC7.html)
MX (2) MX384964B (cg-RX-API-DMAC7.html)
RU (1) RU2727451C2 (cg-RX-API-DMAC7.html)
WO (1) WO2016090369A1 (cg-RX-API-DMAC7.html)

Families Citing this family (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2776698T3 (es) 2012-12-20 2020-07-31 Purdue Research Foundation Células T que expresan un receptor antigénico quimérico como terapia contra el cáncer
RU2763795C2 (ru) 2014-04-23 2022-01-11 Джуно Терапьютикс, Инк. Способы выделения, культивирования и генетической инженерии популяций клеток иммунной системы для адоптивной терапии
JP7098325B2 (ja) 2014-12-05 2022-07-11 シティ・オブ・ホープ Ｃｓ１標的化キメラ抗原レセプター改変ｔ細胞
CA2973529A1 (en) 2015-01-26 2016-08-04 Cellectis Cll1-specific multi-chain chimeric antigen receptor
CN108350462B (zh) 2015-09-11 2022-05-27 生物权威（英国）有限公司 嵌合抗原受体及其用途
EP3408297A2 (en) 2016-01-29 2018-12-05 Med Manor Organics, (P) Ltd A chimeric antigen receptor specific to b-cell maturation antigen, a recombinant expression vector and a method thereof
PE20190356A1 (es) 2016-04-01 2019-03-07 Kite Pharma Inc Receptores quimericos y metodos de uso de los mismos
KR102427334B1 (ko) 2016-04-01 2022-08-03 카이트 파마 인코포레이티드 키메라 항원 및 t 세포 수용체 및 사용 방법
AU2017240150C1 (en) 2016-04-01 2022-10-27 Kite Pharma, Inc. BCMA binding molecules and methods of use thereof
JP7282521B2 (ja) 2016-04-08 2023-05-29 パーデュー・リサーチ・ファウンデイション Ｃａｒ ｔ細胞療法のための方法および組成物
MX2018015414A (es) * 2016-06-30 2019-08-01 Hoffmann La Roche Terapia de célula t adoptiva mejorada.
CN105949324B (zh) * 2016-06-30 2019-08-27 上海恒润达生生物科技有限公司 靶向gpc3的嵌合抗原受体及其用途
EP3518944A4 (en) * 2016-09-30 2020-06-17 Baylor College of Medicine ADAPTIVE CHIMERIC ANTIGENT RECEPTOR T-CELL DESIGN
US12083148B2 (en) 2017-02-22 2024-09-10 H. Lee Moffitt Cancer Center And Research Institute, Inc. IL13Ra2-binding chimeric antigen receptors
WO2018160622A1 (en) 2017-02-28 2018-09-07 Endocyte, Inc. Compositions and methods for car t cell therapy
US20180280437A1 (en) 2017-03-13 2018-10-04 Kite Pharma, Inc. Chimeric antigen receptors for melanoma and uses thereof
JP2020511498A (ja) * 2017-03-20 2020-04-16 シティ・オブ・ホープＣｉｔｙ ｏｆ Ｈｏｐｅ Ａｌアミロイドーシスの治療のためのｃｓ１標的化キメラ抗原レセプター改変ｔ細胞
ES3010117T3 (en) 2017-03-27 2025-04-01 Hoffmann La Roche Improved antigen binding receptors
JOP20180042A1 (ar) 2017-04-24 2019-01-30 Kite Pharma Inc نطاقات ربط مولد ضد متوافقة مع البشر وطرق الاستخدام
CA3061546C (en) 2017-04-28 2023-09-19 Julius-Maximilians-Universitat Wurzburg Ror1-specific chimeric antigen receptors (car) with humanized targeting domains
EP3661511A1 (en) * 2017-08-01 2020-06-10 Julius-Maximilians-Universität Würzburg Use of flt3 car-t cells and flt3 inhibitors to treat acute myeloid leukemia
CN111034336B (zh) 2017-08-11 2024-04-09 交互数字专利控股公司 多个接入网络之间的业务引导和切换
DK3704230T3 (da) * 2017-11-01 2025-01-02 Juno Therapeutics Inc Fremgangsmåde til generering af terapeutiske sammensætninger af modificerede celler
US11464803B2 (en) 2017-11-14 2022-10-11 Arcellx, Inc. D-domain containing polypeptides and uses thereof
IL274652B2 (en) * 2017-11-14 2025-08-01 Arcellx Inc D-domain containing polypeptides and uses thereof
US11390655B2 (en) 2017-11-16 2022-07-19 Kite Pharma, Inc. Modified chimeric antigen receptors and methods of use
CN112292138A (zh) 2018-01-22 2021-01-29 西雅图儿童医院（Dba西雅图儿童研究所） Car t细胞的使用方法
WO2019161271A1 (en) 2018-02-16 2019-08-22 Kite Pharma, Inc. Modified pluripotent stem cells and methods of making and use
WO2019165237A1 (en) 2018-02-23 2019-08-29 Endocyte, Inc. Sequencing method for car t cell therapy
US20220089718A1 (en) * 2018-05-21 2022-03-24 Biosceptre (Uk) Limited Chimeric antigen receptors with modified linker domains and uses thereof
WO2020009868A1 (en) * 2018-07-03 2020-01-09 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Anti-slamf7 chimeric antigen receptors
EP3830133A1 (en) 2018-08-01 2021-06-09 City of Hope Tag72 targeted chimeric antigen receptor modified t cells for treatment of tag72-positive tumors
WO2020025039A1 (zh) * 2018-08-03 2020-02-06 南京驯鹿医疗技术有限公司 表达嵌合抗原受体的t细胞、该嵌合抗原相关表达载体以及它们的应用
JP7386382B2 (ja) 2018-12-12 2023-11-27 カイト ファーマ インコーポレイテッド キメラ抗原受容体及びｔ細胞受容体並びに使用方法
KR20240122580A (ko) 2019-04-03 2024-08-12 프리시젼 바이오사이언시스 인코포레이티드 마이크로RNA-적응 shRNA(shRNAmiR)를 포함하는 유전자-변형 면역 세포
US20220249560A1 (en) * 2019-05-24 2022-08-11 City Of Hope Ccr4 targeted chimeric antigen receptor modified t cells for treatment of ccr4 positive malignancies
CA3143108A1 (en) * 2019-06-19 2020-12-24 Julius-Maximilians-Universitat Wurzburg Ultramodular igg3-based spacer domain and multi-function site for implementation in chimeric antigen receptor design
CN112442126B (zh) * 2019-09-04 2022-07-29 杭州济元基因科技有限公司 一种抗人cs1抗原的单克隆抗体及其car-t细胞
KR20230010228A (ko) * 2020-05-08 2023-01-18 시애틀 칠드런즈 호스피탈 디/비/에이 시애틀 칠드런즈 리서치 인스티튜트 자연 살해 세포를 표적으로 하는 키메라 항원 수용체 (cars)
EP4158030A4 (en) * 2020-05-27 2024-06-26 The Medical College of Wisconsin, Inc. Improved lentiviral vector transfer plasmid and methods of use
CN114286691B (zh) * 2020-08-06 2024-08-06 武汉思安医疗技术有限公司 Cs1-抗体和抗cs1-car-t细胞
WO2022034022A1 (en) * 2020-08-10 2022-02-17 Julius-Maximilians-Universität Würzburg Siglec-6-binding polypeptides
JP2024500847A (ja) 2020-12-18 2024-01-10 センチュリー セラピューティクス，インコーポレイテッド 適合可能な受容体特異性を有するキメラ抗原受容体システム
WO2022206941A1 (zh) * 2021-04-02 2022-10-06 克莱格医学有限公司 Cs1工程化细胞及其组合物
WO2023107898A1 (en) * 2021-12-06 2023-06-15 The Children's Hospital Of Philadelphia Dual targeting of pediatric malignancies through car t-cells secreting bispecific innate immune cell engagers (bices)
CN116410331B (zh) * 2021-12-31 2024-01-30 合源生物科技(天津)有限公司 靶向cs1的嵌合抗原受体、靶向bcma/cs1的双特异性嵌合抗原受体及其应用
EP4499230A1 (en) * 2022-03-25 2025-02-05 F. Hoffmann-La Roche AG Improved chimeric receptors
CN120344563A (zh) * 2022-12-02 2025-07-18 广州荔泰生物科技有限公司 人cs1 car-t细胞
CN119019554B (zh) * 2023-05-25 2025-08-12 东莞市朋志生物科技有限公司 抗白介素6抗体、检测白介素6的试剂和试剂盒

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2487888C2 (ru) * 2006-06-12 2013-07-20 ЭМЕРДЖЕНТ ПРОДАКТ ДИВЕЛОПМЕНТ СИЭТЛ, ЭлЭлСи Одноцепочечные мультивалентные связывающие белки с эффекторной функцией
WO2013151762A1 (en) * 2012-04-05 2013-10-10 Ac Immune S.A. Humanized tau antibody
WO2014179759A1 (en) * 2013-05-03 2014-11-06 Ohio State Innovation Foundation Cs1-specific chimeric antigen receptor engineered immune effector cells

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2064814C (en) 1989-08-11 2004-06-08 Nicos Anthony Nicola Granulocyte-macrophage colony-stimulating factor receptor and derivatives thereof
WO2006074399A2 (en) * 2005-01-05 2006-07-13 Biogen Idec Ma Inc. Multispecific binding molecules comprising connecting peptides
RU2515108C2 (ru) 2005-08-19 2014-05-10 Эббви Инк Иммуноглобулин с двойными вариабельными доменами и его применения
WO2007047829A2 (en) 2005-10-19 2007-04-26 Laboratoires Serono S.A. Novel heterodimeric proteins and uses thereof
GB0523954D0 (en) 2005-11-24 2006-01-04 Ucb Celltech Bioassays
JP6034696B2 (ja) 2010-02-12 2016-11-30 オンコメッド ファーマシューティカルズ インコーポレイテッド ポリペプチド発現細胞の同定及び単離の方法
PH12013501201A1 (en) 2010-12-09 2013-07-29 Univ Pennsylvania Use of chimeric antigen receptor-modified t cells to treat cancer
EP3594245A1 (en) * 2012-02-13 2020-01-15 Seattle Children's Hospital d/b/a Seattle Children's Research Institute Bispecific chimeric antigen receptors and therapeutic uses thereof
CA2868121C (en) 2012-03-23 2021-06-01 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Anti-mesothelin chimeric antigen receptors
EP3626748A1 (en) * 2014-01-13 2020-03-25 Stephen J. Forman Chimeric antigen receptors (cars) having mutations in the fc spacer region and methods for their use
KR102157924B1 (ko) * 2014-02-14 2020-10-26 셀렉티스 면역 세포들 및 병리 세포들 둘 다에 존재하는 항원을 타겟팅하기 위하여 조작된 면역치료용 세포들
EP3137498A1 (en) * 2014-05-02 2017-03-08 Cellectis Cs1 specific multi-chain chimeric antigen receptor
JP7098325B2 (ja) 2014-12-05 2022-07-11 シティ・オブ・ホープ Ｃｓ１標的化キメラ抗原レセプター改変ｔ細胞
JP2020511498A (ja) * 2017-03-20 2020-04-16 シティ・オブ・ホープＣｉｔｙ ｏｆ Ｈｏｐｅ Ａｌアミロイドーシスの治療のためのｃｓ１標的化キメラ抗原レセプター改変ｔ細胞

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2487888C2 (ru) * 2006-06-12 2013-07-20 ЭМЕРДЖЕНТ ПРОДАКТ ДИВЕЛОПМЕНТ СИЭТЛ, ЭлЭлСи Одноцепочечные мультивалентные связывающие белки с эффекторной функцией
WO2013151762A1 (en) * 2012-04-05 2013-10-10 Ac Immune S.A. Humanized tau antibody
WO2014179759A1 (en) * 2013-05-03 2014-11-06 Ohio State Innovation Foundation Cs1-specific chimeric antigen receptor engineered immune effector cells

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
CHU J. ET AL., CS1-specific chimeric antigen receptor (CAR)-engineered natural killer cells enhance in vitro and in vivo antitumor activity against human multiple myeloma, LEUKEMIA, 2013, v.28, n.4, p.917 - 927. *

Also Published As

Publication number Publication date
CA2969704A1 (en) 2016-06-09
AU2015357485A1 (en) 2017-06-29
JP2022051744A (ja) 2022-04-01
WO2016090369A1 (en) 2016-06-09
RU2017121826A3 (cg-RX-API-DMAC7.html) 2019-07-17
KR20170090495A (ko) 2017-08-07
BR112017011893A2 (pt) 2018-07-24
US10821161B2 (en) 2020-11-03
IL252645A0 (en) 2017-07-31
AU2015357485B2 (en) 2020-10-15
IL280917A (en) 2021-04-29
AU2021200122A1 (en) 2021-03-18
US20210170001A1 (en) 2021-06-10
JP2017537627A (ja) 2017-12-21
EP3227315B1 (en) 2022-11-23
IL290459B1 (en) 2023-07-01
IL252645B (en) 2021-03-25
IL280917B (en) 2022-03-01
MX384964B (es) 2025-03-11
HK1247642A1 (zh) 2018-09-28
RU2017121826A (ru) 2019-01-10
IL290459A (en) 2022-04-01
EP4219530A1 (en) 2023-08-02
CN107429253A (zh) 2017-12-01
US11730797B2 (en) 2023-08-22
KR102558502B1 (ko) 2023-07-20
CA2969704C (en) 2023-05-02
US20170360910A1 (en) 2017-12-21
JP7252379B2 (ja) 2023-04-04
JP7098325B2 (ja) 2022-07-11
US20240009288A1 (en) 2024-01-11
EP3227315A1 (en) 2017-10-11
US12497440B2 (en) 2025-12-16
AU2021200122B2 (en) 2023-02-23
CN107429253B (zh) 2021-11-05
MX2017007250A (es) 2018-02-16
MX2021008498A (es) 2021-08-19
IL290459B2 (en) 2023-11-01
CN114085856A (zh) 2022-02-25

Similar Documents

Publication Publication Date Title
RU2727451C2 (ru) Т-клетки, модифицированные химерным рецептором антигена, нацеленным на cs1
AU2015243927B2 (en) Method and compositions for cellular immunotherapy
AU2018289428B2 (en) Methods and compositions for chimeric antigen receptor targeting cancer cells
KR102630017B1 (ko) 프로그램화된 사멸 1 리간드 1 (pd-l1) 결합 단백질 및 그의 사용 방법
CN113846062B (zh) 用于嵌合抗原受体分子的调控表达的慢病毒载体
KR102877478B1 (ko) 유전 물질을 인간 세포 내로 표적화하여 도입하기 위한 향성-변형 재조합 바이러스 벡터 및 이의 용도
KR102390075B1 (ko) 오르니틴 트랜스카르바밀라아제（ｏｔｃ） 결핍증의 치료에 유용한 조성물
CA3041673A1 (en) Engineered artificial antigen presenting cells for tumor infiltrating lymphocyte expansion
CN114728173A (zh) 用于配体依赖性转录调控的具有异源停止转移序列的新型受体
KR20170076775A (ko) T 세포가 아닌 종양을 표적화하는 서바이빈 특이적인 t-세포 수용체
CN116390937A (zh) 一种包含il-12和抗cd20抗体的融合蛋白及其应用
CN106957859A (zh) 一种用于拯救麻疹病毒、重组麻疹病毒的系统以及方法
KR101970428B1 (ko) 재조합 볼거리 바이러스 제릴린2계 백신
KR20220107233A (ko) Car-nk 세포의 수득 방법
HK40069346A (en) Cs1 targeted chimeric antigen receptor-modified t cells
Anna et al. Promoter’s choice drive CAR-T efficiency
RU2833487C1 (ru) Лечение хронической гранулематозной болезни
CN114621929B (zh) 一种抗肿瘤树突状细胞及其制备方法、表达载体及应用
RU2809246C2 (ru) Рекомбинантные вирусные векторы с модифицированным тропизмом и пути их применения для нацеленного введения генетического материала в клетки человека
CN114207126A (zh) 维斯科特-奥尔德里奇综合征基因归巢内切核酸酶变体、组合物和使用方法
EP1526184A1 (en) Promoter sequences specific for cells of the B lymphoid lineage and pharmaceutical compositions containing the same
HK1248720B (zh) 用於嵌合抗原受体分子的调控表达的慢病毒载体